Vaccinex (NASDAQ:VCNX – Get Free Report) is expected to be releasing its resultson Monday, May 18th. Analysts expect Vaccinex to post earnings of ($73.0380) per share and revenue of $0.05 million for the quarter.
Vaccinex Price Performance
VCNX stock opened at $1.01 on Monday. The business has a fifty day moving average price of $0.98 and a 200 day moving average price of $0.93. Vaccinex has a fifty-two week low of $0.31 and a fifty-two week high of $1.50. The stock has a market capitalization of $2.63 million, a price-to-earnings ratio of -0.02 and a beta of 1.10.
About Vaccinex
Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.
In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.
Read More
- Five stocks we like better than Vaccinex
- Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum
- Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players
- Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery
- 3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
